2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Pain
10
Neoplasms
9
Marijuana Abuse
5
Cancer Pain
5
Glioblastoma
2
Squamous Cell Carcinoma of Head and Neck
1
Signs and Symptoms
1
Recurrence
1
Parasomnias
1
Pancreatic Neoplasms
1
Neuralgia
1
Nausea
1
Multiple Sclerosis
1
Mouth Neoplasms
1
Marijuana Use
1
Diabetes Mellitus
1
Chronic Pain
1
Cachexia
1
Breast Neoplasms
1
Brain Neoplasms
1
Anxiety Disorders
1
Anorexia
1
Advanced Malignant Solid Tumor
1
Advanced Cancer
1
1- Cancer Patients During Chemotherapy Treatment
1
Interventions
Morphine
7
Surveys and Questionnaires
6
Ketamine
5
Fentanyl
4
Sodium Chloride
3
Saline Solution
3
Lidocaine
3
Educational Status
3
Dexmedetomidine
3
Cognitive Behavioral Therapy
3
Anesthetics, Local
3
ziconotide
2
Pregabalin
2
Mindfulness-Based Stress Reduction
2
Hypnosis
2
Control Groups
2
Bupivacaine
2
Botulinum Toxins, Type A
2
Acetaminophen
2
6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine
2
tianeptine
1
siltuximab
1
onabotulinum toxin A
1
nabiximols
1
morphine, naltrexone combination
1
erenumab
1
Yoga
1
Waiting Lists
1
Transcutaneous Electric Nerve Stimulation
1
Tramadol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Chronic Pain
×
nabiximols
×
Clear all
NCT03522467
2019-09-25
COPE
Aurora Cannabis Inc
Phase 2
Unknown
40 enrolled